Advanced Solid Tumor Clinical Trial
— IL BelieveOfficial title:
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 therapy.
Status | Recruiting |
Enrollment | 393 |
Est. completion date | August 2027 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - At least 18 years of age - Demonstrated adequate organ function at screening - Life expectancy >12 weeks as determined by the Investigator - Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception - Participants must have histologically confirmed locally advanced, recurrent, or metastatic solid tumor malignancies that cannot be treated with curative intent (surgery or radiotherapy), with the exception of the neoadjuvant cohorts - Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 - Part 3 and Part 4: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) antibody must have a washout of at least 4 weeks from the last dose and evidence of disease progression per investigator assessment before Cycle 1 Day 1 (C1D1) with the exception of the neoadjuvant cohorts - Participants who have previously received an immunotherapy prior to C1D1 must have any immune-related toxicities resolved to =Grade 1 or baseline (prior to the immunotherapy) to be eligible, with the exception of participants on well controlled physiologic endocrine replacement - Part 3: Neoadjuvant cohorts: participants must have completely resectable disease Key Exclusion Criteria: - Symptomatic central nervous system metastases and/or carcinomatous meningitis - Active autoimmune diseases, regardless of need for immunosuppressive treatment, with the exception of participants well controlled on physiologic endocrine replacement - Any uncontrolled bacterial, fungal, viral, or other infection - Significant cardiac disease - A marked clinically significant baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 ms) [CTCAE Grade 1]) using Fridericia's QT correction formula - Positive for human immunodeficiency virus (HIV) or has known active hepatitis B or C infection - Known hypersensitivity to any study treatment(s) used in the specific study part/cohort - Part 3, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, and Neoadjuvant Melanoma: Participants who have been previously treated with IL-2 or IL-2 variants (all participants), or TLR agonist - Systemic immunosuppressive treatment with the exception for patients on corticosteroid taper (for example, for chronic obstructive pulmonary disease exacerbation). - Vaccination with live, attenuated vaccines within 4 weeks of C1D1 - Treatment with any other anti-cancer systemic treatment (approved or investigational) or radiation therapy within 4 weeks of C1D1 - Part 3: Other active malignancies within the last 2 years - Women who are breastfeeding or have a positive serum pregnancy test during screening |
Country | Name | City | State |
---|---|---|---|
Australia | Ascendis Pharma Investigational Site | Adelaide | South Australia |
Australia | Ascendis Pharma Investigational Site | Southport | Queensland |
Korea, Republic of | Ascendis Pharma Investigational Site | Seoul | Songpa-gu |
United States | Ascendis Pharma Investigational Site | Boston | Massachusetts |
United States | Ascendis Pharma Investigational Site | Canton | Ohio |
United States | Ascendis Pharma Investigational Site | Cincinnati | Ohio |
United States | Ascendis Pharma Investigational Site | Huntersville | North Carolina |
United States | Ascendis Pharma Investigational Site | Nashville | Tennessee |
United States | Ascendis Pharma Investigational Site | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Ascendis Pharma Oncology Division A/S |
United States, Australia, Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Tolerability | Treatment emergent and treatment related adverse events (assessed by NCI CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths. | Through study completion, expected average of 2 years | |
Primary | Maximum Tolerated Dose (MTD) | Determine the maximum tolerated dose by assessing the Incidence of Dose Limiting Toxicities (DLTs), treatment emergent and treatment related adverse events (assessed by NCI CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation and deaths. | Each cycle is 21 days | |
Primary | Recommended Phase 2 Dose (RP2D) | To determine a recommended phase 2 dose of TransCon IL-2 ß/? and combination regimen for further development by evaluating number of patients with treatment-related adverse events as assessed by CTCAE. | 12 months | |
Secondary | Overall Response Rate | Response assessed by RECIST v1.1 | Average of 2 years | |
Secondary | Pathologic Complete Response | Evaluate the pathologic Complete Response (pCR) for anti-tumor activity of TransCon IL-2 ß/? alone or in combination with pembrolizumab, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy in the Neoadjuvant Cohorts | 15 weeks | |
Secondary | Major Pathologic Response | Evaluate the Major Pathologic Response (MPR) for anti-tumor activity of TransCon IL-2 ß/? alone or in combination with pembrolizumab, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy in the Neoadjuvant Cohorts | 15 weeks | |
Secondary | Duration of Response | Time from first documentation of objective tumor response (CR or PR that is subsequently confirmed) to first documentation of disease progression or death due to any cause, whichever occurs first | Average of 2 years | |
Secondary | Time to Response | Time from date of first dose of study treatment to first occurrence of response (CR or PR) | Expected up to 1 year from first dose | |
Secondary | Progression Free Survival (PFS) | Time from date of first dose of study treatment to first documentation of disease progression or death due to any cause | Average of 2 years | |
Secondary | Event free survival (EFS) by RECIST 1.1 | Time from the date of the first dose of study treatment to the occurrence of any of the following: progression of disease that precludes surgery, disease recurrence after surgery, or death from any cause. | 2 years | |
Secondary | Overall Survival (OS) | Time from date of first dose of study treatment to date of death due to any cause | Average of 2 years | |
Secondary | PK Characterization (Cmax) | Maximum observed plasma concentration of TransCon IL-2 ß/? and Free IL-2 ß/? after IV administration of TransCon IL-2 ß/? alone or in combination with other therapies | Average of 2 years | |
Secondary | PK Characterization (Tmax) | Time to reach maximum plasma concentration of TransCon IL-2 ß/? and Free IL-2 ß/? after IV administration of TransCon IL-2 ß/? alone or in combination other therapies | Average of 2 years | |
Secondary | PK Characterization (AUClast) | Area under the plasma concentration curve from time zero to last sampling time at which the concentration is at or above the lower limit of quantification for TransCon IL-2 ß/? and Free IL-2 ß/? after IV administration of TransCon IL-2 ß/? alone or in combination with other therapies | Average of 2 years | |
Secondary | PK Characterization (AUC0-t) | Area under the plasma concentration curve from time zero to time t for TransCon IL-2 ß/? and Free IL-2 ß/? after IV administration of TransCon IL-2 ß/? alone or in combination with other therapies | Average of 2 years | |
Secondary | PK Characterization (t1/2) | Apparent terminal half-life of TransCon IL-2 ß/? and Free IL-2 ß/? after IV administration of TransCon IL-2 ß/? alone or in combination with other therapies | Average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 |